Galapagos Announces Start Of Phase 2 Study With Selective TYK2 Inhibitor, GLPG3667, In Patients With Active Systemic Lupus Erythematosus
Portfolio Pulse from Benzinga Newsdesk
Galapagos has announced the commencement of a Phase 2 study with its selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus.
August 28, 2023 | 8:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Galapagos' announcement of the start of a Phase 2 study with GLPG3667 could potentially boost investor confidence in the company's pipeline.
The commencement of a Phase 2 study indicates progress in the company's pipeline, which could positively impact investor sentiment and potentially the stock price. However, the ultimate impact will depend on the results of the study.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100